Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Short interest on THTX plummets

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Feb 10, 2021 11:37am

78 Views

Post# 32525538

RE:RE:RE:RE:RE:Short interest on THTX plummets

you do if you think there is nothing to move the share price in the short or medium term. All we have for the rest of 2021 is product sales to go on. Oncology data won't start coming out until next year. The confirmation of an already announced phase 3 NASH trial isn't going to move anything

SPCEO1 wrote: Some certainly are going to do that, or already have done that, but I really don't think all 16.7 million new shares are likely to be sellers as soon as the stock hits $2.75 (or $2.50 depending on how or if you want to incorporate a value for the warrants).

jeffm34 wrote: It's a free ride with the warrants. Sell the shares as soon as they are profitable and you still have lots of risk free upside with the warrants.